Dyne Therapeutics, Inc.
DYN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.32 | -0.13 | 0.80 | -0.25 |
| FCF Yield | -8.74% | -9.30% | -3.55% | -2.07% |
| EV / EBITDA | -5.37 | -5.75 | -20.60 | -29.62 |
| Quality | ||||
| ROIC | -16.72% | -17.68% | -14.85% | -14.47% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.85 | 0.92 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 11.33% | -25.13% | -14.06% | -34.38% |
| Safety | ||||
| Net Debt / EBITDA | 4.00 | 3.68 | 4.26 | 4.82 |
| Interest Coverage | -1,231.82 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,522.88 | -1,258.39 | 0.00 | -1,385.33 |